Prostate Cancer - Results from #460

Impact of Clinical Factors on 18F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer: Exploratory Analysis of the Phase 3 SPOTLIGHT Study. August 7, 2024

Artera Announces Expansion of the ArteraAI Prostate Test to Inform Active Surveillance Decisions for Lower Risk Prostate Cancer Patients August 6, 2024

Racial, ethnic, and socioeconomic disparities in rates of stage IV prostate cancer after USPSTF category "D" recommendation against prostate-specific antigen screening: a retrospective cohort study. August 6, 2024

Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer. August 6, 2024

PSA Levels and Mortality in Prostate Cancer Patients. August 6, 2024

Assessing the Heterogeneity of Response of [68Ga] Ga-PSMA-11 PET/CT Lesions in Patients With Biochemical Recurrence of Prostate Cancer. August 6, 2024

Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate Cancer. August 6, 2024

Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Prostate Biopsy: A Systematic Review and Meta-analysis of Prospective Studies. August 6, 2024

Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. August 6, 2024

De-escalation of Monitoring in Active Surveillance for Prostate Cancer: Results from the GAP3 Consortium. August 5, 2024

Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway. August 5, 2024

Salvage treatments after focal therapy for prostate cancer - a comprehensive review. August 5, 2024

Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review. August 5, 2024

Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP). August 5, 2024

Neurologic Symptoms After 177Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience. August 5, 2024

Incidence and Pitfalls of Adipose Tissue Encountered in Prostatic Transurethral Resections and Related Specimens. August 5, 2024

Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. August 5, 2024

LX1 Targets Androgen Receptor Variants and AKR1C3 to overcome Therapy Resistance in Advanced Prostate Cancer. August 5, 2024

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. August 5, 2024

Incidence of prostate cancer in Medicaid beneficiaries with and without HIV in 2001-2015 in 14 states. August 2, 2024

Page 24 of 1436